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Summary 
 Marfan syndrome (MFS) is an autosomal dominant connective-tissue disorder. 
It involves predominantly three systems (skeletal, ocular, and cardiovascular 
systems) and is characterized by highly variable expressivity. The diagnosis relies 
solely on clinical criteria requiring anomalies in at least two systems. By excluding 
the disease locus fibrillin 1 (FBN1) in a large French family with typical 
cardiovascular and skeletal anomalies, we raised the issue of genetic heterogeneity 
in MFS and the implication of a second locus (MFS2). Linkage analyses, performed 
in this family with dispersed anonymous DNA markers, have localized MFS2 to a 
region of less than 9 cM between D3S1293   and D3S1283   which map at 3p24.2-
p25. In this region the highest lod score was obtained for marker D3S2336   at 4.89 
(=0.05). LINKMAP analyses indicated that the most probable position for MFS2 was 
at D3S2335  (multipoint lod score in log base 10 = 5.65). 
 
 
Introduction 
 Marfan Syndrome (MFS) was the founding member of the "heritable disorders 
of connective tissue"1. The cardinal features of this autosomal dominant syndrome 
(estimated incidence of 1/10,000) are prominently observed in three systems: 
skeletal, ocular and cardiovascular2. These pleiotropic manifestations are associated 
with great intra- and interfamilial variability that account for complete (or classic) and 
incomplete (or variant) forms of the syndrome in which only two of the systems are 
affected. The diagnosis of MFS is entirely clinical and still difficult in some cases 
despite the guidelines that were set forth in the Berlin nosology3. Quickly after 
Kainulainen et al. mapped the classic form of MFS to 15q15-q21.3 (ref 4,5), it was 
shown that this chromosomal area harbored the FBN1 gene that encodes fibrillin, the 
major component of connective tissue microfibrills6. FBN1 was definitely implicated 
by the detection of tight linkage6,7 followed by the identification of several mutations 
in MFS patients7,8,9,10. From then on, the concept of genetic heterogeneity was set 
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aside although it had always been suspected to explain the great clinical variability of 
the syndrome. However, FBN1 mutations have been identified in only a fraction of 
MFS patients despite extensive screening. Furthermore, the investigation of 
biosynthesis and extracellular deposition of fibrillin in cultured MFS fibroblasts failed 
to detect any anomaly in approximately 7% of the patients11. Despite high cumulated 
lod scores, these observations show that the issue of genetic heterogeneity should 
not be disregarded in MFS. 
 We have been investigating a large family of more than 170 subjects, 
originating from the south of France, with a connective-tissue disorder. The 
autosomal dominant phenotype segregating in this family associates anomalies in 
two systems, namely the skeleton (tall stature, arm span greater than height, 
arachnodactyly, scoliosis, and pectus) and the heart and the aorta (mitral valve 
prolapse, aortic dilation, aortic dissection or rupture). However, none of the ocular 
features observed in classic MFS (myopia, ectopia lentis) are documented in the 
family12,13. These features are thus characteristic of an incomplete form of Marfan 
syndrome2,3 and this was the initial diagnosis12 since several affected subjects 
fulfilled the Berlin criteria. This family was included in the panel of families that were 
studied by the International Marfan Syndrome Consortium to map the MFS 
gene14,15. The diagnosis of MFS went thus unchallenged until we excluded linkage 
between the family phenotype and the FBN1 and FBN2  fibrillin genes13 that are 
involved in MFS6,7 and congenital contractural arachnodactyly (CCA)6 respectively. 
At that time, the clinical features of all family members were scrutinized and a 
controversy arose because of divergent interpretation of the Berlin criteria. A 
compromise was reached and the terminology "Marfan-like" was provisionally 
adopted13,16,17,18. Since this terminology has been justifiably disputed because 
clinical findings in the majority of individuals in this family are identical to those 
observed in conventional Marfan syndrome16 and since several MFS patients 
displaying no anomaly in fibrillin have been reported11 the implication of a second 
locus (MFS2) could no longer be eluded. Therefore, recognition of genetic 
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heterogeneity in MFS prompted us to attempt localization of MFS2 through exclusion 
mapping in this single exceptional family. 
 
 
Results 
 Exclusion map and 3p assignment 
 One hundred forty four genetic markers from 22 autosomes were tested for 
linkage to the MFS2 locus. These (AC)n microsatellite markers spanning the human 
genome were chosen on two criteria: their informativity and an average distance of 
20 centiMorgans (cM) between adjacent markers19. Each locus was tested for 
linkage to MFS2 with the MLINK program20. The combined data were also analyzed 
with the EXCLUDE program21: a non-overlapping exclusion zone of at least 2685 
cM, corresponding to 93.07% of the total genome, was established from the 
cumulative exclusion intervals for each marker. A strong suspicion for linkage with 
MFS2 was given first by marker D3S1300  with a maximum lod score of 2.53 at 
=0.17. This was the only locus investigated that gave a lod score higher than 1.0. 
For this reason, the EXCLUDE analysis indicated that the most probable position for 
the MFS2 locus was on chromosome 3 with a probability of 100%. 
 The linked marker D3S1300  maps at 3p21 (ref 22) that also harbors a collagen 
gene: COL7A1. Mutations in this gene are associated with Epidermolysis Bullosa 
(EB)23,24. Although the clinical features and histologic alterations of MFS are very 
different from those observed in EB, we investigated a possible identity between 
COL7A1 and the disease locus, since they both map to 3p21. Two intragenic RFLPs, 
PvuII25 and AluI26, and a closely linked anonymous marker, D3S2 (ref 27), were 
studied after PCR amplification. The AluI polymorphism was non-informative and the 
PvuII marker showed a maximum lod score of 1.58 (at =0). However, the MspI 
polymorphism at the D3S2 locus showed two obligate recombinants (IV51 and IV54). 
Thus, the involvement of the COL7A1 gene was excluded. 
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 Microsatellite markers confirm and refine localization on 3p24.2-p25 
  To better define the localization of MFS2, 10 polymorphic markers proximal 
and distal to D3S1300, and spanning a region of 54 cM, were studied: tel-D3S1263, 
D3S1286, D3S1266, D3S1277, D3S1289, D3S1261, D3S1284, D3S1274, D3S1276, 
D3S1281-cen . Table 2 summarizes the pairwise lod scores for these loci. Negative 
lod scores were obtained for the markers proximal to D3S1300. Among the distal 
markers, D3S1286  and D3S1266  gave the highest lod score values of 3.04 (at 
0.10) and 2.47 (at 0.07) respectively. We then investigated a region of 22 cM 
surrounding these two markers and studied 11 other loci: tel-D3S2338, D3S1293, 
D3S1599, D3S2336, D3S1583, D3S1567, D3S2335, D3S2337, D3S1283, D3S1609, 
D3S1619-cen. Positive lod scores were observed for several markers (Table 2). The 
highest lod score was 4.89 at =0.05 for marker D3S2336. Markers D3S1293  and 
D3S1283 were mapped with somatic cell hybrids (R158 and GM11752 (3;21)) to 
3p24.2-p25 (ref 22). 
 Thirteen-marker haplotypes were constructed (from tel-D3S1286 to D3S1619-
cen) (marker order is shown in figure 1). Within these, a unique 6 marker sub-
haplotype (from tel-D3S1599  to D3S2337-cen) was found unrecombined in all 
affected individuals (figure 2). This haplotype is defined by two obligate 
recombinants identified for loci D3S1293 (subject IV55) and D3S1283 (subject IV54). 
These data assign MFS2 to an area of less than 9 cM in the subdistal region of 3p. 
Surprisingly, the 6-marker haplotype is also carried by subjects IV44 and IV86 who 
had always been considered as "unaffected" in the linkage analyses. This 
observation revealed that the penetrance of the disease gene was not complete with 
the clinical criteria that had been used for the classification of family members. To 
refine the most probable position of the disease locus, LINKMAP analyses were 
performed. Since erroneous assumption of penetrance has a strong effect on  (ref. 
28), these analyses were carried out with a penetrance of 0.89 estimated from the 
family data. These analyses (Figure 3) showed that the most probable position of the 
MFS2 gene was at D3S2335  (multipoint lod score in log base 10 = 5.65) thus 
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confirming the regional assignment. However, since lod score variations are slight 
between D3S1599  and D3S2335, all the positions between these two loci are 
almost equally likely. 
 
 
Discussion 
 We have located in 3p24.2-p25 a second gene involved in MFS by exclusion 
mapping. The data from a single family place the gene between two recombinational 
events that define the disease haplotype in the family. Although the clinical features 
are identical to those observed in MFS, this diagnosis could not be made in all 
affected individuals using recognized criteria3,13. Therefore patient status was 
established independently by two of us (G. J. and O. D.) with regard to the actual 
clinical follow-up. Furthermore, to avoid spurious recombination in the genetic 
analyses, 6 patients and two of their parents were scored unknown13. Linkage 
analyses were thus performed under very conservative but not powerful conditions. 
Despite these unfavorable conditions, a maximum lod sore of 4.89 (at =0.05) was 
obtained with marker D3S2336  (Table 1), therefore demonstrating conclusive 
linkage. Careful examination of regional markers showed that two individuals (IV44 
and IV86) scored as "unaffected", carried the disease-related haplotype. Since it is 
highly unlikely that these two subjects are both double recombinants, they reveal 
instances of low or non expressivity. IV44 is an adult female who only presented 
isolated minor skeleton anomalies. IV86, 13 years old when he was first examined, 
showed no clinical alteration13. These subjects show that the penetrance is not 
complete in adults, in contrast with classic Marfan syndrome, but also age-
dependent. Interestingly, the 6-marker haplotype is also found in all the subjects for 
whom no definite diagnosis could be made. These patients (IV16, IV30, IV37, IV84 
and IV88) were always genotyped and scored as "unknown" in the linkage analyses, 
in order to avoid spurious results due to misclassification. It must be noted that the 
clinical findings in these 5 individuals are unchanged since the initial publication13. 
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For the purpose of genetic counselling, all these subjects must now be considered 
as carriers of the disease gene. 
 Our data provide conclusive evidence for the assignment of a second locus 
for MFS to chromosome 3p24.2-p25. Positioning of the disease locus in relation to 
the genetic linkage map indicates that MFS2 is located within a 9 cM interval flanked 
by D3S1293  and D3S1283 . These microsatellite markers map to a region that 
contains 5 cloned genes22: THRB (Thyroid Hormone Receptor Beta), RAF (murine 
leukemia viral oncogene homolog 1), VHL (von Hippel-Lindau disease tumor 
suppressor gene), RARB (Retinoic Acid Receptor Beta) and ATP2B2 (ATPase, 
Ca++ transporting). None of these genes are likely candidates for MFS2. 
Furthermore, close examination of homologous loci in mouse (murine chromosomes 
6 (ref 29), 9 (ref 30), and 16 (ref 31) failed to reveal any disease or developmental 
abnormality that could be related to the Marfan phenotype. Therefore, the 
assignment of MFS2 to 3p24.2-p25 opens the avenue to isolating the disease gene 
by the techniques of positional cloning. 
 For a long time, the extreme clinical variability of MFS had been attributed to 
an underlying genetic heterogeneity. To test this hypothesis, three heterogeneity 
tests were performed: two with the anonymous chromosome 15 markers initially 
reported as linked to the MFS locus5,15 and another with the FBN1 markers32. 
Kainulainen et al.5 and Tsipouras et al.32 found no evidence for genetic 
heterogeneity in a sample of 17 and 28 families respectively. Conversely, Sarfarazi 
et al.15 detected genetic heterogeneity in a sample of 22 families that included our 
French family. However, no heterogeneity was detected among the 21 remaining 
pedigrees. Therefore, heterogeneity went undetected in a sample of 45 families 
(since the families reported by Sarfarazi et al. were part of the sample reported by 
Tsipouras et al.). Despite these findings, the question of genetic heterogeneity of 
MFS has not been completely settled not only because of the debate over the 
terminology that should be adopted for the French family's phenotype but also 
because of the identification of a second MFS family displaying recombination with 
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the FBN1 locus (L. Peltonen, personnal communication). All the above indicate the 
existence of a small level of heterogeneity that was previously undetected. With the 
mapping of MFS2, the issue should be addressed again, not only because admixture 
tests will be more powerful since two candidate loci (FBN1 and MFS2) can now be 
simultaneously tested but also in the interest of patients awaiting unequivocal 
molecular diagnosis for genetic conselling. Finally, the involvement of MFS2 should 
also now be tested in other disorders overlapping MFS. Among these, ectopia lentis 
and CCA have been mapped to FBN1 and FBN2 respectively. However, mitral valve 
prolapse33, familial forms of annulo-aortic ectasia34 and the MASS (mitral valve, 
aorta, skeleton, and skin) phenotype35 are still orphan syndromes. In all these 
diseases, the cardiovascular manifestations strongly overlap the phenotype of the 
French family. Therefore the implication of this locus should be investigated. 
 
 
Methodology 
 Patients and clinical evaluation 
 This large French family (see figure 2)12 was ascertained following the death 
of a 39 year old male subject from aortic dissection. A family investigation was 
undertaken. Subjects at risk underwent careful physical examination, 
echocardiography, and slit-lamp examination. Skeletal findings included 
arachnodactyly, narrow arched palate, pectus excavatum, scoliosis, increased lower-
upper body segment ratio, tall stature, and increased arm span. Cardiovascular 
features were mitral valve prolapse associated with holosystolic mitral regurgitation, 
tricuspid valve prolapse, and dilatation of the ascending aorta. None of the affected 
subjects examined had ectopia lentis. Twenty members who showed major 
cardiovascular or skeletal manifestations and were first-degree relatives of an 
affected member were considered as definitely affected. Seventeen family members 
with no abnormality in any of the systems and 12 subjects who presented with 
isolated minor skeletal or cardiovascular findings, were considered unaffected. 
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Finally no diagnosis could be made for 6 patients who showed minor skeletal 
anomalies and/or borderline aortic dilation or mitral valve prolapse and regurgitation. 
These subjects were scored as "unknown" in the genetic analyses. Complete 
individual clinical features are listed in 13.  
 
 DNA analysis and PCR amplification 
 Blood samples were collected from 59 family members and DNA was isolated 
according to a method described elsewhere36. 
 All PCR amplifications were performed under the following standard 
conditions. Forty ng DNA from each patient were used as template. The PCR was 
carried out in a final volume of 50 l in a microtiter plate, using the Techne PMC3 
thermocycler (Cambridge, England) or a thermocycler able to coamplify 16 microtiter 
plates simultaneously (IAS Products Inc.). The reaction included 5 l of 10 X buffer 
(50 mM KCl, 10 mM Tris HCl pH 9, 1.5 mM MgCl2, 0.1% Triton and 0.01% gelatine), 
50 pmol of each primer and 31 mM each of dATP, dTTP, dGTP and dCTP. Samples 
were overlaid with 20 l of light mineral oil to prevent evaporation. After an initial "hot 
start" at 96°C for 5 min, 1 unit of Taq DNA polymerase (NBL) was added to each 
tube, then 35 cycles consisting of denaturation at 94°C (40s) and annealing-
elongation at 55°C (30s) were carried out followed by an extension step at 72°C for 2 
min. Aliquots from 16 PCR reactions from given DNA samples were pooled, 
precipitated, and resuspended in 5 l of 0.1X TE and 12.5 l of sequencing dye. 
Finally, they were loaded onto a 6% denaturing polyacrylamide DNA sequencing gel. 
Electrophoresis was performed for 3 to 5 h at 40 to 50 mA at 3000V. After transfer 
on Hybond N+ membranes, each forward primer was labelled using terminal 
transferase (Boehringer). Hybridization was performed at 42°C overnight in the 
AMASINO medium37. Autoradiography was carried out after the membranes were 
washed twice in 2XSSC, 0.1% SDS at room temperature. 
 
 Linkage analysis 
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 Pairwise and multipoint analyses were performed using the MLINK and 
LINKMAP subprograms of the LINKAGE package20 assuming an autosomal 
dominant disease gene with a frequency of 0.00002 and equal female to male 
recombination rates. In the MLINK analyses, the penetrance value used was 1.0 
since there was no evidence of skipped generations in the pedigree and since very 
conservative diagnostic criteria were used. Allele frequencies were calculated from 
the study of unrelated members of the family. In the LINKMAP analyses, the 
penetrance value was inferred from family data and was set at 0.89. Furthermore, 
the allelle systems were reduced. 
 The EXCLUDE program21 was used to produce the exclusion map. This 
program estimates 1) the positional likelihood of the disease locus on each 
chromosome, 2) the percentage of probability of a locus to be on any of the 22 
autosomes. 
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